Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled BMD003 in Chinese Adult Patients With Cystic Fibrosis
NCT06963008Phase 1Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMD003 in cystic fibrosis (CF), sponsored by Peking Union Medical College Hospital. Primary endpoint: Adverse Events and Serious Adverse Events at 13 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
BMD003
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06963008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963008.